Two Complete Response Letters from the FDA in roughly two years should have quieted the camrelizumab-rivoceranib story, but Elevar Therapeutics is betting that a granular post hoc cut of its Phase 3 CARES-310 data can reopen that conversation. The analysis heading to the International Liver Cancer Association conference this week focuses on younger patients with unresectable hepatocellular carcinoma, an age-stratified subgroup breakdown drawn from a trial that already showed the combination extended median progression-free survival to 5.6 months against 3.7 months for sorafenib in the overall population. That 1.9-month delta was not enough to carry an NDA across the finish line: the FDA issued its most recent CRL in July 2026, a second rejection for this filing.
The strategic logic of presenting an age-subgroup analysis after a regulatory setback is not subtle. Elevar is signaling that the CARES-310 dataset contains signal the agency has not fully weighed, and that a clinically meaningful PFS benefit holds across all age subgroups is the specific claim being put on the record at a peer audience. Whether that matters to regulators depends entirely on what the CRL cited: if the FDA’s objection was manufacturing, trial conduct, or safety data rather than efficacy, an age-stratified PFS poster does essentially nothing to move the ball. If the objection touched on population-level generalizability, this data could anchor a resubmission argument.
The competitive backdrop makes the timing more complicated. First-line unresectable HCC is no longer a thin field. Atezolizumab plus bevacizumab has been standard of care since 2020, and nivolumab plus ipilimumab earned a first-line approval in April 2025. Each new approved regimen raises the implicit bar for differentiation that a resubmission would need to clear, not on efficacy alone but on the question of where this combination fits in an increasingly crowded sequence.
The single number worth tracking now is the timeline and stated basis of any resubmission to the FDA. If Elevar files and specifies which CRL deficiency the new data package addresses, that narrows the probability of a third rejection considerably. If no resubmission timeline emerges after the ILCA presentation, this conference poster reads less as a regulatory prelude and more as a program in search of a path forward.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
